UPDATE 3-U.S. regulators reject Sanofi's MS treatment Lemtrada

* Drug's prospects were at heart of $20 bln Genzyme takeover

from Reuters: Financial Services and Real Estate http://feeds.reuters.com/~r/reuters/financialServicesRealEstateNews/~3/3mBoaZbnkFY/story01.htm